Ovarian, cervical and endometrial cancer need more treatment options. Platinum-based chemotherapy only works for so long. ASCO 23 delivers with the practice-changing MIRASOL study introducing Mirvetuximab Soravtansine, a novel ADC with efficacy in ovarian cancer. Michael and Josh also discuss the Oval Study (ofranergene obadenovec) and immunotherapy in the DUO-O trial and Keynote 826. Not all trials are equal, and this OftIM ASCO special explores endpoints, hazard ratios and comparisons.Stay tuned for daily ASCO updates from the OFTIM team, Michael and Josh.Studies:MIRASOL: https://meetings.asco.org/abstracts-presentations/226803OVAL: https://meetings.asco.org/abstracts-presentations/218323DUO-O: https://meetings.asco.org/abstracts-presentations/220048Keynote-826: https://meetings.asco.org/abstracts-presentations/220048Many thanks to Merck for supporting this episode. Merck provided virtual access to ASCO 2023 but did not review or approve any part of OftiM's coverage of ASCO.For more episodes, resources and blog posts, visit www.inquisitiveonc.comFind us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at [email protected] courtesy of Taryn SilverMusic courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.

Captain's Log: ASCO Day 3.Today's episode brought myriad developments in treating CNS cancers and brain metastases from other distant lands. Some studies offered new and exciting targets for potential treatments. Others purported to provide benefits in new and exciting ways, eschewing infusions and tablets with vaccinations. Still, others repurposed old technology in new ways, investigating uses for things we already had.Unfortunately, many of the solutions were premature and primitive in their exploration. Much further study is required. We will continue to observe these trials for outcomes, but we hope they will yield answers in our quest to fight the disease plaguing our crew.Studies discussed:Anti-PD-1 + GITR + RTx: https://meetings.asco.org/abstracts-presentations/218240UCPVax: https://meetings.asco.org/abstracts-presentations/219832Pembrolizumab in CNS metastases: https://meetings.asco.org/abstracts-presentations/218261Many thanks to Merck for supporting this episode. Merck provided virtual access to ASCO 2023 but did not review or approve any part of OftiM's coverage of ASCO.For more episodes, resources and blog posts, visit www.inquisitiveonc.comFind us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at [email protected] courtesy of Taryn SilverMusic courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.

Hormone receptor-positive breast cancer again takes centre stage at the ASCO 23 (American Society of Clinical Oncology) Annual Meeting and has reinvented itself over the last two decades. Improvements are occurring in the adjuvant and neoadjuvant setting for both estrogen (ER) and progesterone (PR) positive and the human epidermal growth factor receptor space (HER2). In this episode, Michael and Josh take a closer look at MonarchE (Abemaciclib), NATALEE (Ribociclib), PHERgain (dose de-escalation) and Penelope-B (ctDNA).As the arsenal for treating breast cancer grows, a crowded space means ongoing challenges with sequencing and choice of therapy.Stay tuned for daily ASCO updates from the OFTIM team, Michael and Josh.Studies:MonarchE: https://meetings.asco.org/abstracts-presentations/218406NATALEE: https://meetings.asco.org/abstracts-presentations/218407PHERgain: https://meetings.asco.org/abstracts-presentations/219848Penelope-B: https://meetings.asco.org/abstracts-presentations/220878Many thanks to Merck for supporting this episode. Merck provided virtual access to ASCO 2023 but did not review or approve any part of OftiM's coverage of ASCO.For more episodes, resources and blog posts, visit www.inquisitiveonc.comFind us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at [email protected] courtesy of Taryn SilverMusic courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.

ASCO 23 (American Society of Clinical Oncology) Annual Meeting in Chicago showcased a plethora of cutting-edge trials and research. Upper gastrointestinal cancers such as gastric, pancreatic and hepatobiliary are usually relegated to the backstage, but this year, several exciting and potentially practice-changing studies (not without their limitations).We explore a new PD-1Toripalimab in gastric and gastroesophageal cancer, liposomal irinotecan in NALIRIFOX versus gemcitabine/abraxane in metastatic pancreatic cancer, neoadjuvant FOLFIRINOX in pancreatic cancer and the new HER2 kid on the block zanidatamab, a bispecific monoclonal antibody.Stay tuned for daily ASCO updates from the OFTIM team, Michael and Josh.Studies:Toripalimab + SOX study: https://meetings.asco.org/abstracts-presentations/219777NAPOLI-3 study: https://meetings.asco.org/abstracts-presentations/222090NORPACT-1 study: https://meetings.asco.org/abstracts-presentations/219426HORIZON-BTC-01 study: https://meetings.asco.org/abstracts-presentations/219904Special Mention (not included in the episode)DIPLOMA Study: https://meetings.asco.org/abstracts-presentations/218312Lauren Classification: https://open.acast.com/shows/62d20dbcffef490011c8df4b/episodesMany thanks to Merck for supporting this episode. Merck provided virtual access to ASCO 2023 but did not review or approve any part of OftiM's coverage of ASCO.For more episodes, resources and blog posts, visit www.inquisitiveonc.comFind us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at [email protected] courtesy of Taryn SilverMusic courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.

*SPECIAL EPISODE ALERT*Every year, Josh and Mike cross their fingers and pray to Father Conference-Leave that they can make the pilgrimage to one of the two central sites of Oncology: Madrid for ESMO or Chicago for ASCO. Unfortunately, to this point, Father Conference-Leave has not delivered, and 2023 is no different. However, the cold and wind will not stop our intrepid hosts from parsing the avalanche of potentially practice-changing studies, agents and professional development about to descend on the Windy CitySo, consider today's episode what our American listeners would call an "appetizer," a taste of what may be coming from the American Society of Clinical Oncology Annual Meeting for 2023. This will be followed by a string of episodes breaking the aforementioned avalanche down and examining it with a fine tooth comb, with one episode dedicated to each tumour stream. So, do not adjust your set, as there will be a huge amount of Oncology content coming your way. As well as some helpful hints about North American geography.Many thanks to Merck for supporting this episode. Merck provided virtual access to ASCO 2023, but did not review or approve any part of OftiM's coverage of ASCO.For more episodes, resources and blog posts, visit www.inquisitiveonc.comFind us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at [email protected] courtesy of Taryn SilverMusic courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.

Peripheral neuropathy is a common toxicity of multiple anticancer agents used to treat and cure cancer, including platinum, taxanes and vinca alkaloids chemotherapy. These chemotherapy classes are as ubiquitous for cancer treatment as the sun is to plant photosynthesis. This week on OncoSnacks, Michael and Josh investigate what to do when a patient has peripheral neuropathy and examine existing evidence for prevention, treatment and duration of this sequelae.For more episodes, resources and blog posts, visit www.inquisitiveonc.comFind us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at [email protected] courtesy of Taryn SilverMusic courtesy of:- Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/- SoulProdMusic: https://pixabay.com/users/soulprodmusic-30064790/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.

It is always nice to be able to say the phrase: "This cancer has an excellent prognosis." That is the case with endometrial cancer, which for the majority of sufferers, can be cured and carries an excellent survival. However, there are cases that unfortunately present late, and for these patients, the outlook is significantly more grim.Some oncologists have little experience treating advanced endometrial cancer; for those listeners, this episode is specifically for you! In our 40th episode, Josh will discuss the foundations of endometrial cancer treatment, a topic that is vital but very boring, much like Josh himself. Michael will discuss the new frontier of immunotherapy in dMMR endometrial cancer, something that is transformative and very exciting but also unfortunately irrelevant to the majority of patients, much like Michael.Links to studies discussed in this episode (subscription may be required):GOG0209: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7676887/RUBY: https://www.nejm.org/doi/full/10.1056/NEJMoa2216334For more episodes, resources and blog posts, visit www.inquisitiveonc.comFind us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at [email protected] courtesy of Taryn SilverMusic courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.

COSA President-elect (Clinical Oncology Society Australia), Professor Sabe Sabesan, is the oncologist and doctor we all dreamed of being when starting our medical training. This is a story of adversity, compassion and drive without compromise. Sabe's global journey has taken him to some of the remotest places on earth, with each inflection point creating new challenges and opportunities. We discuss advocacy, the rollout of teletrials to improve equitable access, redefining system issues with the lasagna model and looking after the little guy. Michael and Josh are the OFTIM team and are humbled to share Sabe's story, a tale many of us can only aspire to achieve.For more episodes, resources and blog posts, visit www.inquisitiveonc.comFind us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at [email protected] courtesy of Taryn SilverMusic courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.

On Oncology for the Inquisitive Mind, we like to focus on cancer and available treatment options. However, every oncologist is at his or her best when working hand-in-hand with other specialities. In this, our seventh episode of OncoSnacks, Michael and Josh interview Dr Mark Nolan, a non-invasive cardiologist with a special interest in anti-cancer treatment-induced cardiotoxicity. Mark provides an engaging, comprehensive overview of the diagnosis and management of cardiotoxicity, with a particular focus on the two usual culprits: anthracyclines and anti-HER2 agents. A must listen for anyone who has been confronted with a left ventricular ejection fraction (LVEF) of 40%...I mean 30%... oh, now it's 20%...For more episodes, resources and blog posts, visit www.inquisitiveonc.comFind us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at [email protected] courtesy of Taryn SilverMusic courtesy of:- Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/- SoulProdMusic: https://pixabay.com/users/soulprodmusic-30064790/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice Hosted on Acast. See acast.com/privacy for more information.

Adenoid Cystic Carcinoma (ACC) is a rare cancer commonly found in the head and neck region, arising from glandular salivary tissue. Like many orphan cancers, effective treatments in the metastatic setting are needed desperately. The 5-year survival rate is 80% and declines over time. In this special subseries: Rare Cancer Snapshots, Michael and Josh pour over the evidence for ACC, pathophysiology and the treatment paradigm to date.For more episodes, resources and blog posts, visit www.inquisitiveonc.comFind us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at [email protected] courtesy of Taryn SilverMusic courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.

Lutetium PSMA (Lutetium-177), theranostic medicine and future advances in prostate cancer are coming to an oncology centre near you faster than you can say "novel drug development" and "progression-free survival". This week Michael and Josh conclude their epic prostate cancer trilogy by exploring theranostic medicine and radioactive drug development while looking at the past of the cytotoxic world and the role of cabazitaxel. To ensure we keep your attention, six trials are discussed today, and a shout out to TheraP, the Australian phase 2 trial from the land down under.Links to studies discussed in this episode (subscription may be required):Tropic trial: https://www.thelancet.com/article/S0140-6736(10)61389-X/fulltextCARD trial: https://www.nejm.org/doi/full/10.1056/nejmoa1911206Corn et al: https://pubmed.ncbi.nlm.nih.gov/31515154/TheraP: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00237-3/fulltextVision: https://www.nejm.org/doi/full/10.1056/nejmoa2107322For more episodes, resources and blog posts, visit www.inquisitiveonc.comFind us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at [email protected] courtesy of Taryn SilverMusic courtesy of:- Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/- SoulProdMusic: https://pixabay.com/users/soulprodmusic-30064790/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.

Every feast needs a palate cleanser. Every great work of theatre needs an intermission. Every sports event needs a half-time show. In this way, Oncology for the Inquisitive Mind is no different to Hamilton or the Super Bowl. Here, we provide a little deviation from our ongoing Prostate Cancer Saga to interview Dr Jenny Liu, Oncologist and early drug development (EDD) researcher extraordinaire. Our discussions range from her slightly unusual path to oncology, her previous research and how it is still making waves in the oncological community, and her other great passion: mentorship. Suppose you are interested in Phase One trials, mentorship opportunities (especially in Australia), or simply enjoy Josh dredging up dirt on highly accomplished clinicians. In that case, this is the episode for you!For more episodes, resources and blog posts, visit www.inquisitiveonc.comFind us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at [email protected] courtesy of Taryn SilverMusic courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.

In the second episode of our prostate-cancer series, we investigate the inevitability of castration resistance: the biochemical, radiological and clinical progression of prostate cancer despite the best efforts of the heroic MDT. While this space will likely change in the coming years, with many novel anti-androgen agents displaying efficacy in the HSPC space, the current standards of care for patients include docetaxel and the dynamic duo of abiraterone + prednisolone and enzalutamide. These latter two agents are frequently used in the first line when a patient cannot or is unlikely to tolerate docetaxel chemotherapy.However, there can only be one Lord of the Anti-Androgens, and today Josh and Michael will reveal their preferred agent. Listen on to find out which, and please, contain your excitement.Links to studies discussed in this episode (subscription may be required):PREVAIL: https://www.nejm.org/doi/full/10.1056/nejmoa1405095COU-AA-302: https://www.nejm.org/doi/full/10.1056/nejmoa1209096TAX-327 (cameo only): https://www.nejm.org/doi/full/10.1056/nejmoa040720For more episodes, resources and blog posts, visit www.inquisitiveonc.comFind us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at [email protected] courtesy of Taryn SilverMusic courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.

Endocrinopathies in immunotherapy-related cancer treatment are common! Most of us will experience patients with hyperthyroidism and hypothyroidism regularly and recurrently in everyday practice. The incidence is variable, with some sources stating as high as 40% and others as low as 10%; either way, oncologists and trainees are likely to be close allies with their friendly neighbourhood endocrinologist. This week on Oncosnacks, Michael and Josh are interviewing Dr Dahlia Davidoff, an endocrinologist at North Shore Private Hospital in Sydney. Dahlia completed her specialist training through the prestigious Alfred Health and is currently a PhD student researching endocrine cancers at the Kolling Institute of the University of Sydney.They focus predominantly on thyroid disorders and how to diagnose and optimise these conditions with patients receiving immunotherapyFor more episodes, resources and blog posts, visit www.inquisitiveonc.comFind us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at [email protected] Davidoff details:https://www.davidoffendocrinology.com/Art courtesy of Taryn SilverMusic courtesy of:- Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/- SoulProdMusic: https://pixabay.com/users/soulprodmusic-30064790/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice Hosted on Acast. See acast.com/privacy for more information.

J.R.R. Tolkien. George Lucas. Steven Spielberg. With such seminal trilogies as Star Wars, the Lord of the Rings and Indiana Jones achieving a permanent place in the psyche of everyday life, who would have thought there would be room for more? But fear not, because Michael and Josh are here with their take on the age-old formula, with the first in a trilogy of episodes on prostate cancer. Just as Luke Skywalker discovered his heritage and embarked on an epic quest against the Empire, so too do our heroes take their first steps in a fight of their own, examining two studies that pave the way for the future in hormone-sensitive prostate cancer (HSPC) treatment. Gone are the days of ADT-alone, fading to give way to a newer, brighter future, like the end of Tolkien's Third Age. In summary, one may say of the old vogue of HSPC treatments: "It belongs in a museum!"Have we mentioned that we are MASSIVE nerds recently?Links to studies discussed in this episode (subscription may be required):ARASENS: https://www.nejm.org/doi/full/10.1056/NEJMoa2119115PEACE-1: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00367-1/fulltextFor more episodes, resources and blog posts, visit www.inquisitiveonc.comFind us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at [email protected] courtesy of Taryn SilverMusic courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/Note: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.

Ageism is an inherent bias seen throughout medicine, with cancer adding complexity to an already difficult set of circumstances. Despite our best efforts, we all must face growing older, with time itself being that unstoppable force. Over 50% of all new cancer diagnoses are in the over-65 age bracket, which will climb as ageing populations become a reality across the globe. This week, Michael and Josh interview the charismatically delightful Dr Michael Krasovitksy, a staunch supporter and advocate of self-empowerment, geriatric oncology and self-determination in the oncological world. Multiple thought-provoking topics are covered, including ageism, toxicity, symptom management, geriatric oncology, holistic medicine and how to combat the creeping presence of frailty. We also debate the age-old question: When do we not treat, and how does one have this conversation with the outcome being a guaranteed ticket to "shuffle off this mortal coil"?This is one episode where Michael and Josh might find themselves with more questions than answers.For more episodes, resources and blog posts, visit www.inquisitiveonc.comFind us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at [email protected] courtesy of Taryn SilverMusic courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/ Hosted on Acast. See acast.com/privacy for more information.

This episode of OncoSnacks pays homage to the lack of eyebrows, eyelashes and hair many patients face when undergoing cancer treatment and the resultant alopecia. While chemotherapy is the most wanted agent, it alone is not to blame. Michael and Josh explore the hairy situation of hair loss that faces many of our patients as they navigate a new world of outpatient clinic appointments, infusion centres and a new reality in how they live and look.No eyebrows were injured during the making of this episode.For more episodes, resources and blog posts, visit www.inquisitiveonc.comFind us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at [email protected] courtesy of Taryn SilverMusic courtesy of:- Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/- SoulProdMusic: https://pixabay.com/users/soulprodmusic-30064790/Note: This podcast is for educational purposes only. If you are unwell, seek medical advice Hosted on Acast. See acast.com/privacy for more information.

Today, our intrepid trio once more plunge down 20,000 leagues, exploring the confusing depths, hoping to answer one question: is there any evidence to support using systemic therapy in patients with potentially resectable oligometastatic colorectal cancer? The answer will take them to many dark, barely-explored corners of their profession and will raise more questions than answers. Following in the forebears of many explorers, it may drive them completely mad, or at least madder than they already are. But, to paraphrase Captain Nemo of the Nautilus: "the Earth does not want new continents, but new evidence for patients with resectable metastatic colorectal cancer."Links to studies discussed in this episode (subscription may be required):OLIVIA: https://www.annalsofoncology.org/article/S0923-7534(19)31451-6/fulltext#ec0035Falcone et al.: https://ascopubs.org/doi/10.1200/JCO.2006.09.0928?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmedTRIBE: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00122- /fulltext#:~:text=TRIBE%20was%20an%20open%2Dlabel,were%20recruited%20from%2034%20ItalianFor more episodes, resources and blog posts, visit www.inquisitiveonc.comFind us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at [email protected] courtesy of Taryn SilverMusic courtesy of:- Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/- SoulProdMusic: https://pixabay.com/users/soulprodmusic-30064790/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.

Michael and Josh welcome back Dr Andrew Jensen to help explore part two of OftiM's Head and Neck Cancer exploration party. With localised treatments done and dusted, the metastatic space is a daunting heterogeneous disease group. Twenty years ago, head and neck treatment relied on tried and true chemotherapy, but the last fifteen years have shown great strides regarding treatment options and outcomes. The first leap forward was cetuximab added to a chemotherapy backbone, making it the weapon of choice for oncologists worldwide. But like all great civilisations, pembrolizumab now dominates, showing how it can be effective when combined with existing treatment options.A star-studded episode and one not to be missed!Links to studies discussed in this episode (subscription may be required):NCT00122460- https://www.nejm.org/doi/full/10.1056/nejmoa0802656Keynote 048- https://www.thelancet.com/article/S0140-6736(19)32591-7/fulltextFor more episodes, resources and blog posts, visit www.inquisitiveonc.comFind us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at [email protected] courtesy of Taryn SilverMusic courtesy of:- Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/- SoulProdMusic: https://pixabay.com/users/soulprodmusic-30064790/ Hosted on Acast. See acast.com/privacy for more information.

30 episodes ago, two young doctors took their first steps into the podcasting sphere, stumbling like two newborn foals birthed into a paddock full of fully functioning stallions, presenting a niche. Since then, they have blossomed before your ears into two vaguely competent podcasters, still finding their feet but growing in confidence, if not skill. Our continued existence, we owe entirely to you, our wonderful audience. You are the reason we continue to front up to our microphones every week, often wearing our pyjamas but that's beside the point. What we're trying to say is thank you, from the bottom of our hearts.To express our gratitude, we have prepared a niche episode for our niche podcast, examining the treatment of early head and neck cancer. This topic can befuddle even the most experienced oncologists with its confusing, contradictory cornucopia of confirmatory cancer clues. So listen on, as Michael and Josh try to clear a path through the dense jungle, like Doctor Livingstone BEFORE he went missing. Have I met my metaphor quota yet?Links to studies discussed in this episode (subscription may be required):JCOG1008: https://ascopubs.org/doi/full/10.1200/JCO.21.01293Induction chemotherapy for NPC (Zhang et al.): https://www.nejm.org/doi/10.1056/NEJMoa1905287?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmedFor more episodes, resources and blog posts, visit inquisitiveonc.comFind us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at [email protected] courtesy of Taryn SilverMusic courtesy of:- Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/- SoulProdMusic: https://pixabay.com/users/soulprodmusic-30064790/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.

This episode of OncoSnacks kicks off Michael and Josh's sojourn into the wide world of immune-mediated adverse effects. Inevitably, as most blowhards do, they begin with the lungs. Immune-mediated pneumonitis is not as common as endocrine-axis abnormalities, dermatitis or colitis, but it can be insidious and devastating in equal measure. Such is the potential impact that must be considered in any patient who has received immunotherapy and presents with dyspnoea or a dry cough. Listen to learn more, and you will also know what irAEs and Senator Joseph McCarthy have in common.Guidelines for the management of Immune-Mediated Pneumonitis are available at:https://www.frontiersin.org/articles/10.3389/fonc.2020.01785/full#:~:text=will%20be%20discussed.-,Incidence%20and%20Risk%20Factors,due%20to%20pneumonitis%20(6)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7161534/https://www.eviq.org.au/clinical-resources/side-effect-and-toxicity-management/immunological/1993-management-of-immune-related-adverse-eventsFor more episodes, resources and blog posts, visit www.inquisitiveonc.comFind us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at [email protected] courtesy of Taryn SilverMusic courtesy of:- Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/- SoulProdMusic: https://pixabay.com/users/soulprodmusic-30064790/Note: This podcast is for educational purposes only. If you are unwell, seek medical advice Hosted on Acast. See acast.com/privacy for more information.

Five hundred years ago, Christopher Columbus set forth to explore unknown lands. You might be asking, what do Chris and metastatic hormone receptor-positive breast cancer have in common? The answer lies in his diaries, a tale of two men, with one aptly providing anatomical details of our subject today. While we spend little time exploring Christopher, Michael and Josh meet and greet three famed Cyclin Dependant Kinase Inhibitors (CDK4/6) commonly known as Ribociclib, Abemaciclib and Palbociclib. While not all equal in stature, they have revolutionised metastatic breast cancer and now stand as first-line therapy and the gold standard of treatment. Tune in to find out why! Visit us at your new website, www.inquisitiveonc.com, for our latest episodes, links to resources and musings!Find us on Twitter @InquisitiveOncIf you want us to look at a specific trial or subject, email us at [email protected] courtesy of Taryn Silver. Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/Note: This podcast is for educational purposes only. If you are unwell, seek medical advice, and for health, practitioners ensure you refer to your local institution's guidelines for treatment recommendations. Hosted on Acast. See acast.com/privacy for more information.

For the second time in 2023, Josh and Michael discuss some of the hardest-hitting highlights from a conference; in this case, they dive into five studies that caught their eye at the recent ASCO GU Conference in, in Michael's words, "sunny California." We think he is simply jealous of the fact that Melbourne barely has sunshine for most of the year. Never fear: the amount of grousing about the weather pales in comparison to the clinical pearls, future projections and terrible puns.Studies Discussed: ARASENS, CaboPoint, TALAPRO, HCRN GU14-188, PROpel, TROPHY-U-01, CAPTUREFor more episodes, resources and blog posts, visit inquisitiveonc.comFind us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at [email protected] courtesy of Taryn SilverMusic courtesy of:- Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/- SoulProdMusic: https://pixabay.com/users/soulprodmusic-30064790/Note: This podcast is for educational purposes only. If you are unwell, seek medical advice, and for health, practitioners ensure you refer to your local institution's guidelines for treatment recommendations. Hosted on Acast. See acast.com/privacy for more information.

In this episode of OncoSnacks, Josh and Michael address the classic chemotherapy side effect: nausea. From Terms of Endearment (1983) to ER (2002), from Breaking Bad (2008) to Archer (2011), nausea and vomiting are the most frequently imagined side effects when it comes to chemotherapy. However, we are much better at managing chemotherapy-induced nausea and vomiting (CINV) than we once were; a combination of better antiemetics and move away from highly emetic therapies means patients are usually much better off perspective. Nevertheless, in the words of great ancient oncologist Sun Tzu: "if one knows oneself, and knows the neuronal pathways associated with chemotherapy-induced nausea and vomiting, one need not fear the result of a thousand infusions." Listen on to find out how!Guidelines for management of CINV available at:- https://www.sciencedirect.com/science/article/pii/S2468294220301131- https://www.eviq.org.au/clinical-resources/side-effect-and-toxicity-management/gastrointestinal/7-prevention-of-anti-cancer-therapy-induced-nauseaFor more episodes, resources and blog posts, visit inquisitiveonc.comFind us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at [email protected] courtesy of Taryn SilverMusic courtesy of:- Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/- SoulProdMusic: https://pixabay.com/users/soulprodmusic-30064790/Note: This podcast is for educational purposes only. If you are unwell seek medical advice Hosted on Acast. See acast.com/privacy for more information.

Concluding their Journey to the Centre of the Brain, Michael and Josh tackle one of the most challenging and difficult cancers in modern oncology: high-grade gliomas. All of the usual suspects are here: irrevocable, progressive disease, limited treatment options and a gulf in evidence so large it makes the Grand Canyon look like a muddy footprint. All in all, not the most optimistic of OftiM episodes, but Josh and Michael will tackle it anyway so you don't have to. And remember: always refer your fit GBM patients to a friendly neighbourhood trials unit near you!Links to studies discussed in this episode (subscription may be required):EORTC 26981-22981 NCIC CE3 (aka the “Stupp study"): https://www.nejm.org/doi/full/10.1056/nejmoa043330RTOG 0825: https://www.nejm.org/doi/full/10.1056/nejmoa1308573Brada et al: https://ascopubs.org/doi/full/10.1200/JCO.2009.27.1932?role=tabTaal et al: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70314-6/fulltextWick et al: https://www.nejm.org/doi/full/10.1056/nejmoa1707358For more episodes, resources and blog posts, visit inquisitiveonc.comFind us on Twitter @InquisitiveOncIf you want us to look at a specific trial or subject, email us at [email protected] us at your new website www.inquisitiveonc.com for our latest episodes, links to resources and musings!Art courtesy of Taryn SilverMusic courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/Note: This podcast is for educational purposes only. If you are unwell seek medical advice Hosted on Acast. See acast.com/privacy for more information.

Oncology for the Inquisitive Mind finally embarks on the treacherous journey of neuro-oncology. While researching for this episode, Michael and Josh realised that effective treatments are limited but do not reduce neuro-oncology's complexity. This is a hefty episode covering low-grade gliomas, oligodendroglioma, astrocytomas and the important molecular markers and how these influence survival and prognosis for our patients. It also talks about the new WHO classification of primary brain tumours and how it has affected the interpretation of prior research.Tune in for part one of this special mini-series covering neuro-oncologyLink: https://www.atlasantibodies.com/blog/glioma-classification-and-key-molecular-pathology/External site, no subscription is requiredFor more episodes, resources and blog posts, visit www.inquisitiveonc.comFind us on Twitter @InquisitiveOncIf you want us to look at a specific trial or subject, email us at [email protected] courtesy of Taryn SilverMusic courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/Note: This podcast is for educational purposes only. If you are unwell seek medical advice Hosted on Acast. See acast.com/privacy for more information.

In our second bite-sized episode, Michael and Josh explore the challenge of chemotherapy-induced diarrhoea, a common problem for patients leading to morbidity, hospital admissions, and potentially stopping curative treatments early. While immunotherapy and targeted therapy are not innocent bystanders regarding colitis and bowel problems, chemotherapy has long been the most prominent protagonist of this story. It is essential to identify warning signs, investigate adequately and see the treatment options available to you, the saviour and potential part-time plumber. Tune in and find out more!eviQ reference guide on diarrhea: https://www.eviq.org.au/clinical-resources/side-effect-and-toxicity-management/gastrointestinal/779-treatment-induced-diarrhoea#:~:text=Chemotherapy%2Dinduced%20diarrhoea%20usually%20occurs,cause%20diarrhoea%20at%20other%20times.BC Cancer reference guide on diarrhea:http://www.bccancer.bc.ca/nursing-site/Documents/4.%20Diarrhea.pdfFor more episodes, resources and blog posts, visit www.inquisitiveonc.comFind us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at [email protected] courtesy of Taryn SilverMusic courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.

In the grand, six-month-long tradition of Oncology for the Inquisitive Mind, Josh and Michael provide an update from an international meeting to keep you right up to date with the latest and greatest developments in their field. This week's special is the ASCO GI Symposium, held in Moscone, California, and brought to your ears from Melbourne. From two guys in their pyjamas. Who would much rather be in Moscone, California.At any rate, updates abound in this OftiM special. Listen on so you too can crest the wave of Gastrointestinal Oncology!Studies Discussed: NAPOLI 3, CHECKMATE 648 and 649 updates, SPOTLIGHT, Pemigatinib in FGFR mutant mCRCFor more episodes, resources and blog posts, visit www.inquisitiveonc.comFind us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at [email protected] courtesy of Taryn SilverMusic courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.

Oncology for the Inquisitive Mind returns to its regular broadcasting schedule and discusses metastatic renal cell cancer (ccRCC). As not to be outdone, Josh takes a cultural tangent exploring the world of opera after seeing "The Hours" broadcast through Met: Live in HD. While Josh doesn't sing this episode, he highlights this opera's parallels with cancer patients undergoing treatment. To avoid losing sight of this podcast's purpose, Michael and Josh soon find their way. They discovered that metastatic renal cell carcinoma has many treatment options, including targeted therapy, immunotherapy, or even combining these two modalities! Tune in to find out where the evidence currently stands.Links to studies discussed in this episode (subscription may be required):CHECKMATE 214: https://www.nejm.org/doi/full/10.1056/nejmoa1712126KEYNOTE-426: https://www.nejm.org/doi/full/10.1056/NEJMoa1816714 Other studies of interest: CLEAR: https://www.nejm.org/doi/full/10.1056/NEJMoa2035716CheckMate 9ER: https://www.nejm.org/doi/full/10.1056/nejmoa2026982For more episodes, resources and blog posts, visit www.inquisitiveonc.comFind us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at [email protected] courtesy of Taryn SilverMusic courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.

This is OncoSnacks, a new, fortnightly OftIM spinoff!In this new bite-sized series, Michael and Josh try to sink their teeth into more slice-of-life topics, all to help you, our beloved listeners, digest some of the most common problems your patients will serve to you on a platter. This week, a treatment side effect that actually stops people eating (and making lame food-based puns as well): mucositis.This common side effect of anti-cancer systemic therapy can have a major impact on patients quality of life, frequently leading to hospitalisations, significant morbidity and nasogastric tubes galore. But how do we manage such a troublesome problem? Listen on to find out!eviQ reference guide on mucositis: https://www.eviq.org.au/clinical-resources/side-effect-and-toxicity-management/oropharyngeal/210-oral-mucositis-and-stomatitisFor more episodes, resources and blog posts, visit www.inquisitiveonc.comFind us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at [email protected] courtesy of Taryn SilverMusic courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.

This week on Oncology for the Inquisitive Mind, Michael dons his cultural hat and begins with an Ode to the Kidneys, organs that are as much a muse for poets worldwide as the heart (probably). However, you didn't come to this podcast for excellent poetry being delivered with all the panache and misguided enthusiasm of a walrus stepping on a piece of LEGO, and Michael and Josh aim to deliver on this front. Our intrepid pair examine the controversial world of adjuvant treatment of clear cell renal cell cancers (ccRCC), an area of research littered with the ghosts of negative or equivocal studies. But, not every study can be a FLAURA or a DESTINY, and negative studies are just as important, so listen on to find out exactly what NOT to do. Truly, an OftIM first!Links to studies discussed in this episode (subscription may be required):ASSURE: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5591751/KEYNOTE-564: https://www.nejm.org/doi/full/10.1056/NEJMoa2106391For more episodes, resources and blog posts, visit www.inquisitiveonc.comFind us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at [email protected] courtesy of Taryn SilverMusic courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.

As the southern hemisphere basks in summer's beautiful warmth, Michael and Josh skip the beach to explore skin cancer. While melanoma usually takes centre stage in the oncological world, it is far less common than basal cell carcinoma or squamous cell carcinoma. Metastatic squamous cell carcinoma now has a viable and effective treatment option called cemiplimab. At the other end of the spectrum, Michael investigates the very rare cancer type Merkle Cell Carcinoma and how Avelumab has changed its treatment paradigm. Once again, it's immunotherapy at its best. So remember, while listening to our podcast, don't forget to wear a hat and apply sunscreen generously!Links to studies discussed in this episode (subscription may be required):Migden et al. (Cemiplimab): https://www.nejm.org/doi/10.1056/NEJMoa1805131?url_ver=Z39.88JAVELIN Merkel 200 (Cohort B): https://jitc.bmj.com/content/9/7/e002646For more episodes, resources and blog posts, visit inquisitiveonc.comFind us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at [email protected] courtesy of Taryn SilverMusic courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.

New year, new episode of Oncology for the Inquisitive Mind! After enjoying their holiday break, Josh and Michael dive right into 2023 with an episode especially aimed at trainees just about to start their new professional journey in Medical Oncology. Joined by an old friend, the wise-beyond-his-years Dr Andrew Jensen, they discuss life as a trainee, balancing work and life, and how to navigate the tough first few years of life in training, which can so often feel like being a bottle cast into a storm. Join us for an episode that may be light on hazard ratios and p values, but heavy on practical tips and wisdom, delivered in the tone of three dads drinking beer by a campfire...For more episodes, resources and blog posts, visit inquisitiveonc.comFind us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at [email protected] courtesy of Taryn SilverMusic courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.

Oncologists love pushing the limits of what is possible for our patients. To celebrate this and the 20th episode of Oncology for the Inquisitive Mind, Michael and Josh explore the heights of pioneering treatment for early-stage triple-negative breast cancer (TNBC). A notoriously resistant cancer with no known targetable lesions that affect younger women on average, The BrighTNess trial, Keynote 522 and Create-X show just how far the treatment landscape has changed in the last five years.Tune into our final episode for the year! We will return in early 2023 with more content, interviews and hilarious banter.On a final note, Dr Michael Fernando has been admitted to the Royal Australian College of Physicians (RACP), the equivalent of being board certified! Michael has completed this arduous training and is now a fully-fledged Medical Oncologist! Do not distress listeners. Despite no longer being a trainee, Michael will continue on as presenter and host extraordinaire for this podcast.Links to studies discussed in this episode (subscription may be required):BrighTNess trial: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30111-6/fulltextKeynote 522: https://www.nejm.org/doi/full/10.1056/NEJMoa1910549Create-X: https://www.nejm.org/doi/full/10.1056/NEJMoa1612645For more episodes, resources and blog posts, visit www.inquisitiveonc.comFind us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at [email protected] courtesy of Taryn SilverMusic courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.

"I'm not in danger; I AM the danger!" So said Bryan Cranston's Walter White, and so too said early-stage lung cancer when confronted with adjuvant chemotherapy (maybe). In this episode, however, Josh and Michael follow in the footsteps of Hank Schrader, Steve Gomez et al., discussing ways to tackle one of the biggest killers in oncology. While we may not have found a way to control early-stage lung cancer, new developments are on the horizon, such as neoadjuvant chemo-immunotherapy and adjuvant osimertinib. So listen on, with the disclaimer that any similarities between Walter White and Jane Eyre are purely coincidental, no matter what Josh may argue...Links to studies discussed in this episode (subscription may be required):CHECKMATE-816: https://www.nejm.org/doi/10.1056/NEJMoa2202170ADAURA: https://www.nejm.org/doi/full/10.1056/NEJMoa2027071For more episodes, resources and blog posts, visit www.inquisitiveonc.comFind us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at [email protected] courtesy of Taryn SilverMusic courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.

In this episode, Josh and Mikey travel back millions of years to a time when dinosaurs roamed the Earth, as recent research has demonstrated, unmolested by cancer. Then they come crashing back to the present to discuss this week's topic, metastatic colorectal cancer. Will they discover secrets hidden across the aeons? Was the secret to cancer treatment hidden in the bones of our scaled precursors? No, of course not. But there will be a lot of information on the improving treatment of colorectal cancer, which has not taken millions of years to advance. Oh, and Michael does a passable Richard Attenborough.Links to studies discussed in this episode (subscription may be required):FIRE-3: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70330-4/fulltextKEYNOTE 177: https://www.nejm.org/doi/full/10.1056/NEJMoa2017699BEACON: https://www.nejm.org/doi/full/10.1056/NEJMoa1908075Epidemiological Study of Tumours in Dinosaurs: https://link.springer.com/article/10.1007/s00114-003-0473-9For more episodes, resources and blog posts, visit www.inquisitiveonc.comFind us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at [email protected] courtesy of Taryn SilverMusic courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.

Movember is an important event focussing on men's health, including cancer. Prostate cancer is the most common male cancer diagnosed in Australia and the second most common in American men. To highlight this and explore the pioneering treatments available, Michael and Josh interviewed the esteemed Dr Megan Crumbaker. Megan is a medical oncologist specialising in genitourinary cancer and works at The Kinghorn Cancer Centre and St. Vincents Health in Sydney, Australia. Dr Crumbaker completed her undergraduate at Rice University, Texas, before completing her medical training in Sydney and a PhD in prostate genomics through The Garvan Research Institute.We discussed all things prostate oncology with Megan, including research, career, pioneering treatment options and all things prostate cancer. These treatment pearls are not to be missed by any budding oncologist!For more episodes, resources and blog posts, visit www.inquisitiveonc.comFind us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at [email protected]: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.

After looking at early upper gastrointestinal cancers last week, Michael and Josh take the logical next step and discuss the management of their metastatic cousins, the most unsavoury collection since Cassius and Brutus teamed up to assassinate their erstwhile friend Julius. And while our weapons against these cancers are limited, that will not stop our intrepid podcasting pair from taking a deep, rambling and irreverent dive into the dirty details. Friends! Oncologists! Countrymen! Lend us your ears!Links to studies discussed in this episode (subscription may be required):TOGA: https://www.thelancet.com/article/S0140-6736(10)61121-X/fulltextCHECKMATE 649: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00797-2/fulltextCHECKMATE 648: https://www.nejm.org/doi/full/10.1056/NEJMoa2111380For more episodes, resources and blog posts, visit inquisitiveonc.comFind us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at [email protected] courtesy of Taryn SilverMusic courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.

As we CROSS into another episode, Michael and Josh explore the world of early gastric cancer and esophageal cancer. Interestingly both these cancers have a higher incidence in Asia and North Africa. Your podcast hosts soon find early detection of these cancers can be difficult, often leading to treatment challenges not seen by other cancer streams, such as bowel or breast cancer. Unlike previous episodes, FLOT4 looks at perioperative chemotherapy and its benefits over the previous incumbent chemotherapy. Before we give anything more away, make sure to listen to this episode to understand the gold standard of care for these cancers. Likes to the trials below!Links to studies discussed in this episode (subscription may be required):CROSS: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00040-6/fulltexFLOT4: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32557-1/fulltextFor more episodes, resources and blog posts, visit www.inquisitiveonc.comFind us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at [email protected] courtesy of Taryn SilverMusic courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.

After the highs of their special interview with Dr Belinda Yeo on all things breast cancer, Josh and Michael crash back to their usual programming with a banter and dad-joke-filled journey through the treatment of advanced ovarian cancer. A notoriously insidious disease, ovarian cancer is responsible for not just significant mortality but soul-crushing morbidity as well. However, for some very special people, ovarian cancer does not stop them from reaching their goals, up to and including completing a triathlon! Listen on for the full, inspiring story!Links to studies discussed in this episode (subscription may be required):PAOLA-1: https://www.nejm.org/doi/full/10.1056/nejmoa1911361AURELIA: https://ascopubs.org/doi/10.1200/jco.2013.51.4489Leslie Medley-Russell, Ovarian Cancer Survivor: https://www.mdanderson.org/cancerwise/two-time-ovarian-cancer-survivor--never-give-up.h00-159148401.htmlFor more episodes, resources and blog posts, visit inquisitiveonc.comFind us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at [email protected] courtesy of Taryn SilverMusic courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.

To celebrate the end of breast cancer awareness month, Michael and Josh are joined by Dr Belinda Yeo, an experienced oncologist specialising in treating breast cancer. Belinda trained at St Vincent's Hospital in Sydney, Australia, followed by the Royal Marsden Hospital in London. She now works at the Olivia Newton-John Cancer Research Institute as a Clinician Scientist with a specific interest in breast cancer and the prestigious Austin Hospital in Melbourne, Australia.We discussed all things breast oncology with Belinda, including career path, research, patient-centred care and, of course, all the breast cancer treatment pearls for any budding oncologist!This is one episode not to miss!For more episodes, resources and blog posts, visit www.inquisitiveonc.comFind us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at [email protected]Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.

In this episode, Josh and Michael take a step down from the dizzying heights of HER-2 positive breast cancer treatment and crash back to earth to metastatic pancreatic cancer, a topic that remains an unconquered Everest, mocking oncologists like that one kid who always stole Josh's lunch money in school... Don't worry; there will be no airing of childhood trauma here. Just two oncologists discussing treatments and casting a hopeful eye towards the future.Links to studies discussed in this episode (subscription may be required):ACCORD-11: https://www.nejm.org/doi/full/10.1056/nejmoa1011923MPACT: https://www.nejm.org/doi/full/10.1056/nejmoa1304369For more episodes, resources and blog posts, visit www.inquisitiveonc.comFind us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at [email protected] courtesy of Taryn SilverMusic courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.

In part two of their HER2 breast cancer dive, Josh and Michael explore the optimistic world of metastatic breast cancer. Once a desolate space with limited options, HER2 metastatic breast cancer represents the frontier of targeted therapy, like the industrial age or landing on the moon. While neither Josh nor Mikey have been to the moon, these researchers have landed among the stars bringing hope and effective treatments to an aggressive tumour time that a decade ago would have had a very different story. Links to studies discussed in this episode (subscription may be required):CLEOPATRA: https://www.nejm.org/doi/full/10.1056/nejmoa1413513Destiny-Beast03: https://www.nejm.org/doi/10.1056/NEJMoa2115022For more episodes, resources and blog posts, visit www.inquisitiveonc.comFind us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at [email protected] courtesy of Taryn SilverMusic courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.

In this episode, Josh and Michael begin their second two-part expedition, this time exploring HER2-positive breast cancer, an area of oncology that has been much like your favourite Instagram or TikTok celebrity: at the forefront of the hottest new trends. Neither Josh nor Mikey have a favourite Instagram or TikTok celebrity because they are old and out of touch, but the shifts in HER2-positive breast cancer may be their favourite oncological TikTok celebrity. For the reasons behind such a stretched analogy, listen on!Links to studies discussed in this episode (subscription may be required):NeoSphere: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70336-9/fulltextKATHERINE: https://www.nejm.org/doi/full/10.1056/nejmoa1814017For more episodes, resources and blog posts, visit www.inquisitiveonc.comFind us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at [email protected] courtesy of Taryn SilverMusic courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.

In this episode, Josh and Michael once again tackle immunotherapy in its application to metastatic urothelial cancer. Some say immunotherapy should be used up front. Others say that it should be used when all previous treatments have failed. And still, others are wondering about that Richard Nixon/Spock impression from last week and how it could be topped. For answers to all those questions and more, you'll have to listen on...Links to papers discussed in this episode (subscription may be required):JAVELIN-100: https://www.nejm.org/doi/full/10.1056/NEJMoa2002788KEYNOTE 045: https://www.nejm.org/doi/full/10.1056/nejmoa1613683For more episodes, resources and blog posts, visit www.inquisitiveonc.comFind us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at [email protected] courtesy of Taryn SilverMusic courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.

In this extraordinary episode, Josh and Michael continue their journey to the earth's centre and the unknown with more European Society of Medical Oncology (ESMO) highlights. Since last week, Michael has realised that his French needs a bit of work, so they stuck to their guns and avoided google translate. Josh feels they should work on their Spanish to prepare for ESMO in Madrid in 2023. But before these dashing young Doctors get too excited for next year, more pivotal studies must be reported for your enjoyment! This episode focuses on colorectal, and Michael dabbles in some genitourinary and skin research.Find us @InquisitiveOnc for fun oncology facts and links to the latest episodes!All abstracts discussed in this episode are available from https://oncologypro.esmo.org. ESMO membership may be required.Colorectal: FRESCO-2, NICHE-2, MOUNTAINEER, CAIRO5Genitourinary: RADICALS-HD, COSMIC 313;Skin: SWOG1801; Neoadjuvant Cemiplimab (NEJM)For more episodes, resources and blog posts, visit inquisitiveonc.comFind us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at [email protected] courtesy of Taryn SilverMusic courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.

In this very special episode, Josh and Michael hope to fulfil their fantasy of attending the European Society of Medical Oncology's (ESMO) yearly Congress, where they rub elbows with oncology's biggest movers and shakers; learn about the latest groundbreaking studies; and, in Michael's case, speak French with an accent lifted from a Monty Python sketch. The fact that they were stuck at home for the entire conference won't stand in the way of them from highlighting some of the best, most exciting studies presented in Paris.Find us @InquisitiveOnc for fun oncology facts and links to the latest episodes!All abstracts discussed in this episode are available from https://oncologypro.esmo.org. ESMO membership may be required.Lung: ADAURA, CODEBREAK 200, INCREASE, IPSOS, Checkmate 816, APPLEBreast: BELLINI, TROPiCS-02Upper GI: LEAP-002, PRODIGE-65-UCGI-36-GEMPAX, RLY-4008For more episodes, resources and blog posts, visit inquisitiveonc.comFind us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at [email protected] courtesy of Taryn SilverMusic courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/Fanfare theme courtesy of StudioKolomna: https://pixabay.com/users/studiokolomna-2073170/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.

"Hepatobiliary cancer, the final frontier." So begins our double-headed sojourn into two of the most challenging to-treat cancers many oncologists will encounter, but one that ends on a surprisingly positive note. Also, there's a cameo that absolutely no one will see coming...Links to studies discussed in this episode (subscription may be required):TOPAZ-1: https://evidence.nejm.org/doi/full/10.1056/EVIDoa220001IMbrave150: https://www.nejm.org/doi/10.1056/NEJMoa1915745Barcelona Liver Cancer Staging: https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/fb5943f9-9201-4128-848a-626d744c651f/gr1_lrg.jpgSource: Reig M, et al. "BCLC strategy for prognosis prediction and treatment recommendation: the 2022 Update." Journal of Hepatology. November 2021. Available from: https://doi.org/10.1016/j.jhep.2021.11.018Art courtesy of Taryn SilverMusic courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.